Effects of Persistent Atrial Fibrillation on Serum Galectin-3 Levels - 17/02/15
, Hande Canpinar, PhD b, Banu Evranos, MD a, Hikmet Yorgun, MD a, Mehmet Levent Sahiner, Assoc Prof a, Ergun Baris Kaya, Assoc Prof a, Necla Ozer, Prof a, Lale Tokgozoglu, Prof a, Mehmet Ali Oto, Prof a, Dicle Guc, Prof b, Kudret Aytemir, Prof aAbstract |
Galectin-3 is known to play an important role in a number of fibrotic conditions, including cardiac fibrosis. Many studies have focused on the association between galectin-3 levels and cardiac fibrosis in heart failure. However, the role of galectin-3 in the pathogenesis of atrial fibrillation (AF) has not been evaluated thoroughly yet. The aim of this study was to determine whether serum galectin-3 levels were elevated in patients with AF and preserved left ventricular function. Seventy-six patients with paroxysmal or persistent AF and preserved left ventricular systolic function and 75 age- and gender-matched control subjects were enrolled in this observational study. Galectin-3 levels were measured by enzyme-linked immunosorbent assay. Serum galectin-3 (median 0.6 ng/ml [interquartile range 0.2 to 1.4] vs 0.5 ng/ml [interquartile range 0.1 to 0.7], p <0.001) and left atrial volume index (LAVI) (mean 29.5 ± 3.5 vs 26.5 ± 2.5 ml/m2, p <0.001) were significantly greater in patients with AF compared with the control group. Serum galectin-3 levels were also significantly higher in patients with persistent AF than those with paroxysmal AF (median 0.8 ng/ml [interquartile range 0.4 to 1.4] vs 0.5 ng/ml [interquartile range 0.2 to 0.9], p <0.001). Multivariate regression analysis demonstrated that serum galectin-3 (odds ratio 87.53, 95% confidence interval 6.06 to 1,265.03, p = 0.001) and LAVI (odds ratio 1.38, 95% confidence interval 1.19 to 1.60, p <0.001) were independent predictors of AF. Only LAVI was independently correlated with serum galectin-3 levels in patients with AF in linear regression analysis. In conclusion, serum galectin-3 is significantly elevated and is also significantly correlated with LAVI in patients with AF with preserved left ventricular function.
Le texte complet de cet article est disponible en PDF.Plan
| This project was funded by Hacettepe University Scientific Research Projects Coordination Unit (grant number 1993). |
|
| See page 650 for disclosure information. |
Vol 115 - N° 5
P. 647-651 - mars 2015 Retour au numéro
Article précédent
- Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit)
- Ashish D. Patel, Mary K. Tan, Paul Angaran, Alan D. Bell, Murray Berall, Claudia Bucci, Andrew M. Demchuk, Vidal Essebag, Lianne Goldin, Martin S. Green, Jean C. Gregoire, Peter L. Gross, Brett Heilbron, Peter J. Lin, Krishnan Ramanathan, Allan Skanes, Bruce H. Wheeler, Shaun G. Goodman
- Usefulness of Ventricular Premature Complexes in Asymptomatic Patients ?21 Years as Predictors of Poor Left Ventricular Function
- Karine Guerrier, Jeffrey B. Anderson, Richard J. Czosek, Wayne A. Mays, Christopher Statile, Timothy K. Knilans, David S. Spar
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?